Unicycive Therapeutics, Inc. (UNCY)Healthcare | Biotechnology | Los Altos, United States | NasdaqCM
7.02 USD
+0.12
(1.739%)
⇧
(April 17, 2026, 4 p.m.
EDT)
After hours: 7.08 +0.06 (0.855%) ⇧ (April 17, 2026, 7:22 p.m. EDT) Short-term: ★★☆☆☆ | Long-term: ★☆☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 11, 2026, 4:16 p.m. EDT
UNCY presents a volatile and speculative opportunity with a recent price range between $6.11 and $7.12, and a 52-week low of $3.71. The stock's fundamentals are weak, with negative earnings and a low forward P/E, but the recent news about potential NDA resubmission and analyst recommendations suggest some optimism. The options activity indicates a mix of bearish and bullish bets, making it a high-risk, high-reward play. For short-term traders, the current price could be a buying opportunity if there's a bullish momentum shift, but long-term investors should be cautious due to the lack of sustainable fundamentals and consistent dividends. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.037581 |
| AutoETS | 0.042037 |
| AutoARIMA | 0.042803 |
| AutoTheta | 0.051158 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 80% |
| H-stat | 0.63 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.480 |
| Excess Kurtosis | -0.27 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 0.387 |
| Market Cap | 177,169,232 |
| Forward P/E | 0.82 |
| Beta | 1.80 |
| Website | https://unicycive.com |
As of April 11, 2026, 4:16 p.m. EDT: Options speculators are showing mixed signals. The high implied volatility (IV) and open interest (OI) in puts, particularly around the $2.5 strike, suggest potential bearish sentiment, while calls on the $7.5 strike indicate some bullish positioning. However, the presence of top OI on out-of-the-money (OTM) puts and the overall volatility patterns suggest uncertainty about future price direction. The market may be anticipating a significant move, but the lack of clear directional consensus makes it risky for short-term traders.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.15081966 |
| Address1 | 4,300 El Camino Real |
| Address2 | Suite 210 |
| All Time High | 87.3 |
| All Time Low | 2.02 |
| Ask | 8.81 |
| Ask Size | 2 |
| Average Analyst Rating | 1.3 - Strong Buy |
| Average Daily Volume10 Day | 543,120 |
| Average Daily Volume3 Month | 556,056 |
| Average Volume | 556,056 |
| Average Volume10Days | 543,120 |
| Beta | 1.801 |
| Bid | 5.04 |
| Bid Size | 2 |
| Book Value | 1.365 |
| City | Los Altos |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 7.02 |
| Current Ratio | 2.585 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 7.0771 |
| Day Low | 6.87 |
| Debt To Equity | 0.387 |
| Display Name | Unicycive Therapeutics |
| Earnings Timestamp End | 1,747,221,300 |
| Earnings Timestamp Start | 1,747,221,300 |
| Ebitda | -29,483,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -4.613 |
| Enterprise Value | 136,017,232 |
| Eps Current Year | 0.71125 |
| Eps Forward | 8.576 |
| Eps Trailing Twelve Months | -1.67 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 6.6836 |
| Fifty Day Average Change | 0.33640003 |
| Fifty Day Average Change Percent | 0.050332163 |
| Fifty Two Week Change Percent | 15.081966 |
| Fifty Two Week High | 11.0 |
| Fifty Two Week High Change | -3.98 |
| Fifty Two Week High Change Percent | -0.3618182 |
| Fifty Two Week Low | 3.71 |
| Fifty Two Week Low Change | 3.31 |
| Fifty Two Week Low Change Percent | 0.89218324 |
| Fifty Two Week Range | 3.71 - 11.0 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,626,096,600,000 |
| Float Shares | 22,818,236 |
| Forward Eps | 8.576 |
| Forward P E | 0.8185634 |
| Free Cashflow | -22,924,500 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 21 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.024939999 |
| Held Percent Institutions | 0.34027 |
| Implied Shares Outstanding | 25,237,782 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,021-07-13 |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,750,377,600 |
| Last Split Factor | 1:10 |
| Long Business Summary | Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies to address unmet medical needs in the United States. Its drug candidates include UNI 494, a pro-drug of Nicorandil that is being developed as a treatment for acute kidney injury; and Renazorb RZB 012 for the treatment of hyperphosphatemia in patients with chronic kidney disease. The company also evaluates licensing of technologies and drugs for orphan diseases, other renal, liver, and other metabolic diseases affecting fibrosis and inflammation. Unicycive Therapeutics, Inc. has license agreements with Shilpa Medicare Ltd to develop and commercialize oxylanthanum carbonate; Sphaera Pharma Pte. Ltd.; Syneos Health LLC to develop of UNI-494; Inotiv for preclinical trial and related services for oxylanthanum carbonate and UNI-494; Lee's Pharmaceutical (HK) Limited; and Lotus International Pte Ltd for the development, registration filing, and approval for oxylanthanum carbonate. The company was incorporated in 2016 and is based in Los Altos, California. |
| Long Name | Unicycive Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 177,169,232 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_605176729 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -26,555,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 176,916,851 |
| Number Of Analyst Opinions | 8 |
| Open | 7.05 |
| Operating Cashflow | -31,317,000 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 650 351 4495 |
| Post Market Change | 0.059999943 |
| Post Market Change Percent | 0.8547 |
| Post Market Price | 7.08 |
| Post Market Time | 1,776,468,179 |
| Previous Close | 6.9 |
| Price Eps Current Year | 9.869947 |
| Price Hint | 2 |
| Price To Book | 5.142857 |
| Profit Margins | 0.0 |
| Quick Ratio | 2.179 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.25 |
| Region | US |
| Regular Market Change | 0.12 |
| Regular Market Change Percent | 1.73913 |
| Regular Market Day High | 7.0771 |
| Regular Market Day Low | 6.87 |
| Regular Market Day Range | 6.87 - 7.0771 |
| Regular Market Open | 7.05 |
| Regular Market Previous Close | 6.9 |
| Regular Market Price | 7.02 |
| Regular Market Time | 1,776,456,000 |
| Regular Market Volume | 390,692 |
| Return On Assets | -0.45661998 |
| Return On Equity | -1.41145 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 25,237,782 |
| Shares Percent Shares Out | 0.0723 |
| Shares Short | 1,825,494 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 1,961,264 |
| Short Name | Unicycive Therapeutics, Inc. |
| Short Percent Of Float | 0.0743 |
| Short Ratio | 4.0 |
| Source Interval | 15 |
| State | CA |
| Symbol | UNCY |
| Target High Price | 90.0 |
| Target Low Price | 15.0 |
| Target Mean Price | 39.8925 |
| Target Median Price | 34.5 |
| Total Cash | 41,269,000 |
| Total Cash Per Share | 1.635 |
| Total Debt | 117,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.67 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 5.484975 |
| Two Hundred Day Average Change | 1.5350251 |
| Two Hundred Day Average Change Percent | 0.27986002 |
| Type Disp | Equity |
| Volume | 390,692 |
| Website | https://unicycive.com |
| Zip | 94,022 |